Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – FitzGerald Website

David J. FitzGerald, Ph.D.

Selected Publications

1)  Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ.
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.
J. Biol. Chem. 265: 20678-85, 1990.
[Journal]
2)  FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, Winkles JA, Strickland D, Leppla S.
Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein.
J. Cell Biol. 129: 1533-41, 1995.
[Journal]
3)  Mansfield E, Amlot P, Pastan I, FitzGerald DJ.
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Blood. 90: 2020-6, 1997.
[Journal]
4)  Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, Fitzgerald DJ.
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Mol. Cancer Ther. 9: 2007-15, 2010.
[Journal]
5)  Antignani A, Sarnovsky R, Fitzgerald DJ.
ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including Pseudomonas exotoxin.
Mol. Cancer Ther. 13: 1655-63, 2014.
[Journal]
6)  Liu XF, Xiang L, FitzGerald DJ, Pastan I.
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Mol. Cancer Ther. 13: 82-9, 2014.
[Journal]
7)  Hollevoet K, Antignani A, Fitzgerald DJ, Pastan I.
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
J. Immunother. 37: 8-15, 2014.
[Journal]
8)  Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I.
Immunotoxins for leukemia.
Blood. 123: 2470-7, 2014.
[Journal]
9)  Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O' Shea JJ, Pastan IH, FitzGerald DJ.
Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts.
J. Immunol. [Epub ahead of print], 2014.
[Journal]
10)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/20/2014.